IAPP and Alzheimer disease: While many papers in the AD field have been focused on amylin's self-aggregation like Aβ (Gotz et al., 2009; DeToma et al., 2012), probably equal attention needs to be given to the potential benefits of soluble amylin or its non-amyloidgenic analogs for the AD brain.